Characteristics of women with rheumatoid arthritis who participated in the PARA study and had a follow-up assessment in 2015/2016 (N=128)
| Variables | Variables | ||||
|---|---|---|---|---|---|
| Age (years) | Anti-rheumatic drugs at follow-up | ||||
| At first visit | 31.8±3.8 | MTX | 65 (51%) | ||
| At follow-up | 42.6±4.4 | Prednisone | 16 (13%) | ||
| Sulfasalazine | 15 (12%) | ||||
| Age at menarche (years) | 13.1±1.4 | Hydroxychloroquine | 17 (13%) | ||
| Missing | 9 (7.0%) | Leflunomide | 5 (3.9%) | ||
| Smokers at first visit | 9 (7.0%) | Biologicals—total n (%) | 71 (55%) | ||
| Missing | 2 (1.6%) | Etanercept | 29 (23%) | ||
| Infliximab | – | ||||
| Disease characteristics | Certolizumab | 2 (1.6%) | |||
| Duration of disease (years) | Adalimumab | 20 (16%) | |||
| At first visit | 4.8 (2.1–10.4) | Golimumab | 3 (2.3%) | ||
| At follow-up | 15.8 (12.7–21.5) | Abatacept | 6 (4.7%) | ||
| Missing | 1 (0.8%) | Rituximab | 2 (1.6%) | ||
| Presence of ACPA, n (%) | 78 (61%) | Tocilizumab | 9 (7.0%) | ||
| Presence of RF, n (%) | 85 (66%) | ||||
| Presence of erosions, n (%) | 77 (60%) | Use of MTX | |||
| Missing | 3 (2.3%) | Ever used MTX | 113 (88%) | ||
| Missing | 2 (1.6%) | ||||
| Hormone use at follow-up | Cumulative duration of MTX use | ||||
| None | 62 (48%) | Never used | 13 (10%) | ||
| Oral contraceptive pill | 25 (20%) | Less than 1 year | 12 (9.3%) | ||
| Levonorgestrel releasing IUD | 37 (29%) | 1 to 5 years | 27 (21%) | ||
| Injectable progesterone | 2 (1.6%) | 5 to 10 years | 31 (24%) | ||
| Missing | 2 (1.6%) | >10 years | 25 (20%) | ||
| Missing | 20 (16%) | ||||
| Cumulative years MTX in users | 5.8 (2.2–10.2) | ||||
ACPA, anti-citrullinated protein antibodies; IUD, intra-uterine device; MTX, methotrexate; PARA, pregnancy-induced amelioration of rheumatoid arthritis; RF, rheumatoid factor.